Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ Enriched Transplants for Myeloid Malignancies
NCT05565105Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Jan 2034
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML) and 2 more. Primary endpoint: Overall Survival at 2 years. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)chronic myelomonocytic leukemia (CMML)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05565105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565105.